-+ 0.00%
-+ 0.00%
-+ 0.00%

ARROWHEAD PHARMACEUTICALS COMPLETES ENROLLMENT IN GLOBAL PHASE 3 YOSEMITE STUDY OF ZODASIRAN FOR THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Reuters·07/27/2026 11:30:00

Please log in to view news